drug · antibody
mirikizumab
Marketedupdated 3mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
indications
investigational
IBD (Crohn's + UC)
targets
Interleukin-23
all catalysts(5)
approval · 5
Oct 26, 2023
approval
$LLY1183.16+0.25%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Apr 29, 2024
approval
$LLY1183.16+0.25%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
$LLY1183.16+0.25%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
$LLY1183.16+0.25%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Oct 23, 2025
approval
$LLY1183.16+0.25%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Trials studying mirikizumab
- phase2A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- phase2LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- phase3A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
- phase3Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- phase2A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- phase3Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- phase2A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- phase1A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that